|
|
|
 |
FDA Approval Activities for this Drug…
Omnicef (cefdinir) Capsules, Abbott NDA 50-739/S-006 7/24/02 8/6/02 Omnicef (cefdinir) Capsules, Parke-Davis NDA 50-739/S-002 11/24/99 12/30/99 12/30/99 Omnicef (cefdinir) Powder Suspension Parke-Davis NDA 50-749/SE2-002 7/14/99 7/29/99 7/29/99 Omnicef Indication: 5-day dosing regimen (7 mg/kg BID) for the treatment of AOM Omnicef (cefdinir) for Oral Suspension, Abbott Laboratories, Control Supplement Omnicef (cefdinir) capsules, Abbott Laboratories, Labeling Revision | Omnicef (cefdinir) capsules, Abbott Laboratories, Labeling Revision | Omnicef (cefdinir) powder for oral suspension, Abbott Laboratories, Labeling Revision | Cefdinir Capsules, Lupin Ltd., Approval | Cefdinir Oral Suspension, Lupin Ltd., Approval | Cefdinir Capsules, Sandoz Inc., Approval | Cefdinir Oral Suspension, Sandoz Inc., Approval | Cefdinir Oral Suspension, Teva Pharma, Approval | Cefdinir Capsules, Teva Pharma, Approval | OMNICEF (cefdinir) Capsules, Abbott Labs, Labeling Revision | OMNICEF Oral Suspension, Abbott Labs, Labeling Revision | Cefdinir Capsules, Orchid Healthcare, Approval | Cefdinir Oral Suspension, Orchid Healthcare, Approval | OMNICEF (cefdinir) Capsules, Abbott Labs, Labeling Revision | OMNICEF (cefdinir) Oral Suspension, Abbott Labs, Labeling Revision | Cefdinir Oral Suspension, Aurobindo Pharma, Approval | Cefdinir Capsules, Aurobindo Pharma, Approval | Omnicef (cefdinir) Capsules, Abbott Laboratories, Labeling Revision | Omnicef (cefdinir) Oral Suspension, Abbott Laboratories, Labeling Revision
  
|